The company postponed the deployment of its vaccine in the EU due to information about thrombosis among those vaccinated with Janssen.
The American company Johnson & Johnson has postponed the start of use in Europe of its Janssen coronavirus vaccine – because of information about the formation of blood clots in people who took it.
This is stated in today’s statement by J&J.
“We have decided in advance to postpone the deployment of our vaccine in Europe,” the document says.
The company, together with European health authorities, is studying data on thrombosis among vaccinated people, as well as working with experts on this issue and advocating for ” open communication of this information to medical professionals and the public.”
Earlier in the day, the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) recommended suspending the use of the Johnson & Johnson coronavirus vaccine.
According to their data, for 6.8 million doses of the Johnson & Johnson vaccine administered in the United States, six cases of “rare and complex” cases of thrombosis were detected.
That is, blood clots were formed in 0.0001% of patients. All the victims were women aged 18-48 years, and the side effect appeared in the 6-13 days after vaccination.
Against this background, a meeting of the CDC’s Advisory Committee on Immunization Practices will be convened on April 14 to assess the potential significance of such cases. The FDA also considers information about thrombosis in vaccinated patients.
“Until this process is complete, as a precautionary measure, we recommend pausing the use of this vaccine,” said CDC Deputy Director Anna Schuchat and director of the FDA’s Center for Biologics Evaluation and Research Peter Marks.
Earlier, similar side effects were found in the AstraZeneca vaccine. This was officially confirmed by the European Medicines Agency, but the reason for this connection remains unclear.
For its part, the World Health Organization noted the high effectiveness of the J&J vaccine against new coronavirus mutations.
